anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Advance care planning (ACP) is an important component of palliative care (PC), and is a critical, ongoing dialogue between health care professionals (HCPs), patients, and families; where patients' comprehension of their illness and illness progression, goals of care, and treatment choices are discussed. Essential to ACP is the interdisciplinary team, where each member must be comfortable and confident initiating conversations about quality of life and end-of-life (EOL) care. ACP is often hindered by low health literacy, including PC health literacy, uncertainty regarding illness trajectory and end-of-life palliative care (EOLPC) options, and lack of awareness about ACP among patients. For HCPs, discomfort, lack of EOL communication training, and knowledge of cultural differences are often barriers to ACP. Foundational to ACP is PC health literacy, which necessitates considering semantics, eliminating misconceptions, and recognizing uncertainty. Ensuring access to ACP for patients with serious life-limiting illness requires that all healthcare disciplines receive evidence-based EOLPC communication training. The COMFORT communication curriculum (CC) is an intervention that trains interdisciplinary HCPs to provide patient- and family-centered EOLPC communication. Patient outcomes related to this intervention have not been studied. Moreover, the curriculum's efficacy and fit has not been specifically tested with minority groups. Native Americans (NA) are disproportionately affected by serious life-limiting conditions and life expectancy is 4 years less than all other US races. Despite greater morbidity and mortality, NAs use of PC is largely unknown. Yet, it has been identified that tribal communities are requesting EOLPC services and will participate in ACP when conducted in a culturally-respectful manner. There is an urgent need to develop culturally-relevant communication approaches specific to EOLPC, including ACP, for use with NAs with serious life-limiting illness. The investigators propose a collaborative clinical trial to: 1) Culturally-adapt the COMFORT CC for pilot testing with NA communities; 2) Implement the culturally-adapted COMFORT CC in 2 tribal communities by training 20 interdisciplinary (nurses, social workers, primary care providers) HCPs to conduct culturally-respectful and relevant ACP; 3) Conduct a pilot, wait-list controlled trial of the culturally-adapted COMFORT CC in 2 tribal communities to evaluate feasibility, acceptability, and perceived effectiveness by comparing 30 NAs completing ACP with a trained HCP and 30 NAs receiving usual care. Implementing a culturally-relevant communication intervention to improve EOLPC health literacy is a high priority for the Rosebud and Pine Ridge reservations in South Dakota. This proposed study will culturally-adapt and evaluate the COMFORT CC on these 2 reservations and will provide the foundation for an R01-funded intervention study that could positively impact EOLPC literacy and outcomes among the 566 US federally recognized NA tribes.
There is an urgent need to address sub optimal catheterisation that men experience when living in the community with urinary retention problems. The catheters currently used within the NHS in the community settings are typically of the Intermittent or 'Foley' type. Foley types are based on a nearly 100-year-old design. An inflatable balloon, filled with water anchors one end within the bladder. At the other end, external to the body, a bag collects the urine, or a valve allows its discharge. Intermittent catheters are instead inserted multiple times daily in order to empty the bladder, before being removed. The amount of times an intermittent is swapped out for a new one depends on the patient's condition and the frequency is guided by a Health Care Professional. This study will compare the cymactive™ catheter and foley type catheters.

This study has been designed as a pMDCS and is therefore the second phase of medical device assessment, with the CCD 1st generation device being CE Marked under the MDD. Based upon this and other existing devices, such as indwelling catheters, and prostatic stents, we are confident that the device is safe. ACCTUATE is a single-centre study for the assessment of the cymactive™ catheter device (referred to as CCD) both in terms of reduction of individuals' historic CAUTIs incidence associated with implementation, and in terms of tolerance and acceptability of patients and clinicians. The CCD will be administered as a replacement for a Foley-type device (referred to as FTD)and will be implemented for 30 days prior to removal and replacement with another CCD. This process will be repeated in 3, 30-day cycles. The study will consist of two arms: the CCD arm and the FTD arm. Patients will be recruited equally to each arm of the study.

All participants will receive background local standard of care therapy according to participating institutions/hospitals regardless of the study group to which they belong. 60 participants will be recruited to this study. 30 patients in the CCD arm and 30 patients in the FTD. The study will begin with the recruitment of a Sentinel group of 20 patients consisting of 10 patients randomised to the CCD arm and 10 patients randomised to the FTD arm. Following this, a 4-week recruitment pause will take place in order to undertake an interim data capture of the Sentinel group data. The Sentinel group will continue to participate in the study during this time as detailed in the Schedule of Activities. This will give an opportunity to analyse any AEs/SAEs and patient data from the Sentinel group. Following this, the Study Physician, Coordinating Investigator and Sponsor will agree a date for the recommencement of recruitment to the study.

Participants will be outpatient male adults (≥ 18 years) with a documented history of urinary retention based on a postvoidal residue scan, cystoscopy, urodynamic test or alternative diagnostic means; and catheter use and bladder-capacity issues on a long-term basis (\>4 weeks).
Approximately 50 subjects at multiple sites will crossover to receive both treatments (lacosamide \[LCM\]and carbamazepine immediate release \[CBZ-IR\]) in a randomized order during the 2 study treatment periods (Treatment Period 1 and Treatment Period 2).

A Screening Visit will be conducted to evaluate subject eligibility for enrollment into the study. Eligible subjects will return up to 21 days after the Screening Visit and begin Treatment Period 1. During Visit 2, eligible subjects will be randomized to receive either LCM 300 mg/day or CBZ-IR 600 mg/day. Subjects will be treated with their first randomized Antiepileptic Drug (AED) for 6 weeks (Titration Period \[21 days\] and Maintenance Period \[21 days\]). Subjects then complete a 28-day Taper/Washout Period, during which their first AED will be tapered over 4 days followed by a 24-day Washout Period, where subjects will receive no AED. Upon completion of the Taper/Washout Period, subjects will begin Treatment Period 2.The procedures and assessments for Treatment Period 1 will be repeated for Treatment Period 2 (with the same duration of treatment).
1) Polymorphic crystal modification B (form B) of telmisartan (formula I),   characterised by an endothermic maximum at 183+-2 degree C which occurs during thermal analysis using DSC. 2) Telmisartan, characterised in that it contains form B according to claim 1. 3) Process for preparing telmisartan according to one of claims 1 and 2, characterised in that a) telmisartan is taken up in a mixture of solvents consisting of water, formic acid and an organic solvent miscible therewith, heated, and the resulting solution is then filtered, b) the organic solvent is distilled off, optionally while water is simultaneously added in metered amounts, c) the telmisartan form B is precipitated out of the remaining solution by the addition of a base and d) the product precipitated is centrifuged, washed and dried. 4) Process according to claim 3, characterised in that organic carboxylic acid esters, ketones or ethers are used as the organic solvent. 5) Process according to claim 3 or 4, characterised in that acetone, methylethylketone, methyl acetate, ethyl acetate, ethyl formate, ethyleneglycol dimethylether or tetrahydrofuran is used as the organic solvent. 6) Process according to claim 3, 4 or 5, characterised in that acetone, methylethylketone, methyl acetate, ethyl acetate or tetrahydrofuran is used as the organic solvent. 7) Process according to claim 3, 4, 5 or 6, characterised in that ethyl acetate is used as the organic solvent. 8) Process according to claim 3, 4, 5, 6 or 7, characterised in that ammonia is used as the base. 9) Use of telmisartan for preparing a pharmaceutical composition.
PURPOSE: Dysfunctions of retinal pigment epithelium (RPE) attributed to oxidative stress and inflammation are implicated with age-related macular degeneration (AMD). A debate on the curative role of metformin in AMD has been raised, though several recent clinical studies support the lower odds by using metformin. This study aimed to determine whether metformin could exert cytoprotection against RPE oxidative damages and the potential mechanisms.
METHODS: A cellular AMD model was established by treating ARPE-19 cells with hydrogen peroxide (H2O2) for 24 h. The reactive oxygen species (ROS) generation, expression of antioxidant enzymes, and levels of pro-inflammatory cytokines were monitored under administrations with H2O2 with/without metformin. The expression and DNA-binding activity of transcription factor erythroid-related factor 2 (Nrf2) were determined by western blot, immunofluorescence, and electrophoretic mobility shift assay. Knockout of Nrf2 was conducted by CRISPR/Cas9 gene deletion system.
RESULTS: Metformin pretreatment significantly improved the H2O2-induced low viability of ARPE-19 cells, reduced ROS production, and increased contents of antioxidative molecules. Concurrently, metformin also suppressed levels of pro-inflammatory cytokines caused by H2O2. The metformin-augmented nuclear translocation and DNA-binding activity of Nrf2 were further verified by the increased expression of its downstream targets. Genetic deletion of Nrf2 blocked the cytoprotective role of metformin.
CONCLUSION: Metformin possesses antioxidative and anti-inflammatory properties in ARPE-19 cells by activating the Nrf2 signaling. It supports the potential use for the control and prevention of AMD.
Patients will be randomly assigned to receive placebo at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression or withdrawal of consent.
Hypoxia in coastal ecosystems is increasing as a result of water quality declines from nutrient pollution. Hypoxia negatively affects fish populations and marine life, limiting their spawning habitats, population size, and growth. In this study, two approaches were used to understand the effect of hypoxia on the chorusing and reproductive behavior of fishes in estuaries. One approach used a water quality meter integrated with a prototype passive acoustic recorder, developed to monitor dissolved oxygen and fish chorusing simultaneously and continuously at sites with normoxic and hypoxic conditions. In a second approach, passive acoustic recorders were deployed near ambient water quality monitoring stations, monitored by the North Carolina agencies in estuaries where hypoxia occurs periodically. In both approaches, when hypoxia (dissolved oxygen < 4.0 mg/L) occurred, fish chorusing was diminished or ceased. A strong correlation was observed between bottom water dissolved oxygen and the power spectral density in a 100-200 Hz frequency band associated with red drum (Sciaenops ocellatus, Sciaenidae) calling. Passive acoustic monitoring stations and integrated passive acoustic and water quality meters should be used in estuarine hypoxia monitoring efforts to examine the expanding areas of hypoxia and its impact on fish critical spawning habitats.
PURPOSE:To obtain an antagonist having endothelin receptor antagonistic action and useful for the treatment of hypertension, acute renal insufficiency, etc., by using non-peptide pheophorbide derivative as an active component. CONSTITUTION:The antagonist contains a derivative of formula [R1 is CH3 or CHO; R2 is H or (esterified) carboxyl] as an active component. The antagonist administered by oral administration (e.g. in the form of tablet, pellet, etc., at a rate of 0.1-100mg/kg/day) or parenteral administration (e.g. in the form of injection at a rate of 0.01-20mg/kg/day). The compound of formula can be produced by extracting a photosynthetic organism with an organic solvent such as methanol or ethyl acetate and purifying the extract by chromatography, etc. The compound of formula is preferably pheophorbide a (R1 is CH3 and R2 is carboxymethyl), etc.
Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 70-99% stenotic carotid plaque with associated neurological symptoms. ARFI ultrasound imaging will be performed on the carotid plaque.
Drug delivery systems suitable for administration into the interior of an eye of a person or animal are described. The present systems include one or more components which are effective in improving a release profile of a drug from the system, improving the stability of the drug, and improving the ocular tolerability of the drug. The present systems include one or more therapeutic agents in amounts effective in providing a desired therapeutic effect when placed in an eye, and an excipient component with reduced toxicity to retinal cells. The excipient component may include a cyclodextrin component that may be complexed with the therapeutic agents to provide advantages over existing intraocular drug delivery systems. The cyclodextrin component of the present systems have a reduced toxicity relative to benzyl alcohol or polysorbate 80. The drug delivery systems include one or more drug delivery elements such as microparticles, bioerodible implants, non-bioerodible implants, and combinations thereof. Methods of using and producing the drug delivery systems are also described.
Subjects on a stable dose of hydroxyurea will be treated with increasing doses of subcutaneous erythropoietin (EPO) as tolerated for an initial 12 weeks, during which the main safety and efficacy endpoints (including the primary endpoint of hemoglobin response) will be assessed. Subjects may continue on treatment for an additional 12 weeks as clinically indicated, with assessment of additional endpoints at the end of the 24-week study period.
Triazolam tablets are contraindicated in patients with known hypersensitivity to this drug or other benzodiazepines.

Benzodiazepines may cause fetal damage when administered during pregnancy. An increased risk of congenital malformations associated with the use of diazepam and chlordiazepoxide during the first trimester of pregnancy has been suggested in several studies. Transplacental distribution has resulted in neonatal CNS depression following the ingestion of therapeutic doses of a benzodiazepine hypnotic during the last weeks of pregnancy.

Triazolam is contraindicated in pregnant women. If there is a likelihood of the patient becoming pregnant while receiving triazolam, she should be warned of the potential risk to the fetus. Patients should be instructed to discontinue the drug prior to becoming pregnant. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered.

Triazolam is contraindicated with ketoconazole, itraconazole, and nefazodone, medications that significantly impair the oxidative metabolism mediated by cytochrome P450 3A (CYP 3A) (see WARNINGS and PRECAUTIONS–Drug Interactions).
The liver parenchyma is crushed with a Pean clamp and subsequently divided using Covidien Endo-Gia™ Ultra Handle Short Staplers and Endo Gia™ TRI staple 60 mm or 45 mm AVM/AMT loading units (Covidien). Hepatic veins and portal pedicles clamped and suture ligated.
The present invention relates to a composition containing quercetin for preventing or treating malignant pleural mesothelioma or aiding treatment of malignant pleural mesothelioma. The composition for preventing or treating malignant pleural mesothelioma or aiding treatment of malignant pleural mesothelioma is characterized to containing quercetin. Quercetin regulates the expression of Sp1 regulatory gene such as Cyclin D1, Mcl-1, and Survivin in MS TO-211H cells. A cell death signal transduction is activates by isolating proteins, Bid, caspase-3, and PARP, reducing Bcl-xl, and increasing Bax in MSTO-211H cells. The result suggests that Sp1 is a novel molecular target of quercetin in malignant pleural mesothelioma. Therefore, quercetin can be used as an agent for preventing or treating malignant pleural mesothelioma or aiding treatment of malignant pleural mesothelioma.
The invention discloses a probiotics targeting carrier carrying an anti-cancer medicament curcumin and a preparation method thereof. The preparation method includes connecting the curcumin with spore surface of bacillus coagulans by means of an esterification reaction to synthesize and obtain curcumin-probiotics carrier (CUR-Spore); and then connecting the carrier with folic acid by means of the esterification reaction to successfully prepare and obtain probiotics folic acid targeting carrier carrying curcumin (CUR-Spore-FA). The targeting medicament carrier can be used to treat colorectal carcinoma, has targeting, and can reduce the toxic and side effect of the medicament. Moreover, the bacillus coagulans can protect the curcumin in the carrier medicament, so that the carrier drug can tolerate gastric acid to get through the stomach smoothly. The carrier drug can be colonization in the intestine and germination in the intestine to release curcumin for treating colorectal carcinoma. The preparation method improves the utilization rate of curcumin, establishes a targeting conveying system of the anti-cancer medicament, can be used for treating colorectal carcinoma, and provides a novel mode of treating colorectal carcinoma.
The invention discloses a traditional Chinese medicine foot bath health care prescription for treating sweaty feet. The centers of feet of patients of sweaty feet are slightly sweaty, and the socks and shoes of severe patients can even be wetted by the sweats. The feet of patients of sweaty feet usually give off odors. Because feed are soaked by sweat for a long time, the skins between toes are pale, the skins around the toes are red and become hard; tinea pedis happens easily, and the symptoms of rotten skin, cracked skin, and pain happen frequently. The prescription comprises six traditional Chinese herbals by weight: 25 to 35 grams of phellodendron, 25 to 35 grams of calcined dragon bone, 8 to 12 grams of alum, 13 to 17 grams of sophora flower, 13 to 17 grams of Chinese gall, and 13 to 17 grams of curcuma tuber. The preparation and application method comprises the following steps: at first, pouring six traditional Chinese herbals into a marmite, decocting for a half hour, removing the dregs, pouring the decoction into a nonmetal foot basin, adding 3 to 5 kilograms of hot water, which has been boiled for twice and cooled for once and has a temperature of 38 to 40 DEG C, until the ankle joint is submerged by water, and soaking the feet for a half hour. The prescription can treat sweaty feet.
This study seeks to compare the efficacy of single coil defibrillation leads for the internal cardioversion of atrial fibrillation as compared with cardioversion by external defibrillation pads. It is known that dual coil leads are effective for atrial cardioversion, but the presence of the SVC defibrillation coil allows for selection of shock vector that more reliably incorporates the majority of atrial tissue compared to a single right ventricular lead. For a variety of reasons single coil defibrillation leads are now implanted in the majority of patients requiring placement of implantable cardiac defibrillators, and many of these patient's will later develop atrial fibrillation and potentially require cardioversion. Currently, there is no clear consensus on how to approach cardioversion in these patient's and both external and internal methods are used. Internal cardioversion may be ineffective exposing patient's unnecessarily to repeated shocks and battery depletion. External cardioversion may carry a small risk of damaged to the CIED.

The investigator's goal is to identify patient's referred for cardioversion for atrial fibrillation who also have an implanted cardiac defibrillator with a single coil defibrillation lead and randomize them to either external or internal cardioversion.
Avascular necrosis of the femoral head (ANFH) is a debilitating disease that usually leads to destruction of the hip joint in the third to fifth decade of life (average age, 36 years). The disease prevalence is unknown, but it has been estimated that 10,000-20,000 new cases per year are diagnosed in the United State. Nearly half of the patients eventually require hip replacement before 40 years of age. The etiology of ANFH is unknown but previous studies indicated that heritable thrombophilia (increased tendency to form thrombi) and hypofibrinolysis (reduced ability to lyse thrombi), alcohol intake, and steroid use are risk factors for ANFH.

Although the majority of idiopathic ANFH cases are sporadic, recently we identified three ANFH families showing autosomal dominant inheritance. By genome-wide scan, a significant two-point LOD score of 3.45 at = 0 was obtained between one ANFH pedigree and marker D12S85 on chromosome 12. High-resolution mapping was conducted in a second ANFH family and replicated the linkage to D12S368. When an age-dependent penetrance model was applied, the combined multipoint LOD score achieved 6.43 between D12S1663 and D12S85. Furthermore, by using haplotype analysis and gene-based mutation detection, we have identified the collagen type II, alpha 1 (COL2A1) gene, as the ANFH disease gene. Re-sequencing of the type II collagen (COL2A1) gene demonstrated a glycine with serine mutation in the G-X-Y repeat of type II collagen, in all affected individuals in three pedigrees. In the Pedigree I, a 3665G \>A mutation in exon 50 of the COL2A1 gene (Genbank accession number NM_001844) and the substitution resulted in a Gly1170Ser codon change (Genbank accession number NP_001835). A second pedigree was shown to harbor the same mutation but the mutant allele existed in a different haplotype background. In a third pedigree, a 2306G\>A mutation occurred in exon 33 of the gene (Genbank accession number NM_001844), causing glycine to serine change at codon 717 (Genbank accession number NP_001835).

On this basis, we propose to study the pathophysiological mechanism(s) of inherited and sporadic ANFH. The main focus of this project includes: (1) Establishing cell line and animal models to investigate the molecular basis of ANFH pathogenesis. (2) Conducting genetic analysis on sporadic ANFH cases, including those who are idiopathic, alcohol consumers or steroid-induced. (3) Using COL2A1 gene as a target, we will design novel therapeutics and prediction procedures to improve the management of the ANFH patients.
The invention discloses a drug for treating hypertension. The drug is prepared from 10g of selfheal, 10g of lumbricus, 10g of rhizoma alismatis, 10g of prepared rehmannia root and 10g of white peony root. A preparation method of the drug comprises decocting the above materials by water. One dosage of the drug soup is taken every day, a treatment course comprises ten days and the drug is continuously taken for three treatment courses. The drug solves the problem that the existing hypertension treatment drug has large side effects, causes addiction, has long treatment time and a high recurrence rate after administration stopping and cannot thoroughly treat hypertension. The drug is suitable for treating hypertension.